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summary
Influenza A (H5N1) virus with an amino acid substitution in neuraminidase con-
ferring high-level resistance to oseltamivir was isolated from two of eight Vietnam-
ese patients during oseltamivir treatment. Both patients died of influenza A (H5N1) 
virus infection, despite early initiation of treatment in one patient. Surviving pa-
tients had rapid declines in the viral load to undetectable levels during treatment. 
These observations suggest that resistance can emerge during the currently recom-
mended regimen of oseltamivir therapy and may be associated with clinical deteriora-
tion and that the strategy for the treatment of influenza A (H5N1) virus infection 
should include additional antiviral agents.
Influenza A (h5n1) virus causes severe disease in humans and poses an unprecedented pandemic threat.1-3 The neuraminidase inhibitor oseltamivir constitutes an important treatment option, and stockpiling of this drug is part 
of pandemic-preparedness plans.4 However, data on the efficacy and development of 
drug resistance in human influenza A (H5N1) virus are scarce. We report the isola-
tion of oseltamivir-resistant influenza A (H5N1) variants from two patients who 
died of the infection, in one case despite the early initiation of treatment. Further-
more, we provide evidence suggesting that the presence of detectable virus after the 
completion of treatment is associated with a poor outcome. These observations 
have implications for the treatment of influenza A (H5N1) virus infection.
case report
A previously healthy 13-year-old Vietnamese girl weighing 28 kg (Patient 1 in Table 1) 
presented to a hospital in Dong Thap Province on January 22, 2005, with a one-day 
history of fever and cough. The day before, her mother (Patient 2 in Table 1) had 
died of influenza A (H5N1) virus infection after one day of oseltamivir treatment. 
Virus isolated from the mother did not reveal oseltamivir-resistance mutations. Be-
cause influenza A (H5N1) virus infection was suspected in the child at presentation, 
she received an initial 75-mg dose of oseltamivir and was transferred to a pediatric 
referral hospital. On admission, she had a temperature of 40.3°C, a pulse of 106 beats 
per minute, a respiratory rate of 36 breaths per minute, and normal blood pressure. 
Results of physical examination and routine biochemical measurements were unre-
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markable. Hematologic measurements showed a 
white-cell count of 4800 cells per cubic millimeter 
(normal range, 5500 to 15,500), with 12 percent 
lymphocytes, and a platelet count of 183,000 cells 
per cubic millimeter (normal range, 250,000 to 
550,000). A blood culture showed no growth. A 
chest radiograph revealed a small focal pulmo-
nary infiltrate in the right middle lobe (Fig. 1A). 
The patient received a second 75-mg dose of 
oseltamivir within 6 hours after the first, fol-
lowed by a third dose within the first 24 hours 
after admission. Treatment was then continued 
for four days at the standard dose of 75 mg twice 
daily. Antibiotic treatment with ceftriaxone and 
amikacin was also given. During the first three 
days after admission, the patient remained in 
stable condition and did not require supplemen-
tal oxygen. A chest radiograph obtained on Janu-
ary 24 showed minimal progression of the infil-
trate (Fig. 1B). At that time, her white-cell count 
was 3100 cells per cubic millimeter, with 26 per-
cent lymphocytes. 
On January 25 (the fourth day of oseltamivir 
treatment), the child’s respiratory condition wors-
ened and supplemental high-dose oxygen was giv-
en, initially by nasal cannula and later by continu-
ous positive airway pressure. Antibiotic treatment 
was switched to vancomycin, ciprofloxacin, and 
amikacin. At this time, the pneumonia involved 
most of the right middle zone (Fig. 1C). A chest 
radiograph obtained on January 26 showed fur-
ther progression of the infiltrate (Fig. 1D). Hema-
tologic and biochemical measurements revealed 
a white-cell count of 1800 cells per cubic millime-
ter, with 41 percent lymphocytes; a platelet count 
of 97,000 cells per cubic millimeter; and increased 
serum alanine aminotransferase and aspartate 
aminotransferase levels (144 and 279 U per liter, 
respectively; normal range, less than 55 and less 
than 50, respectively). Her respiratory condition 
continued to worsen, and she was intubated and 
ventilation was begun on January 27. A chest ra-
diograph obtained on January 28 showed pneu-
monia involving the entire right lung and exten-
sion to the left lung (Fig. 1E). She died the same 
day. No autopsy was performed.
methods
patients and clinical specimens
We examined sequential pharyngeal swabs from 
Patient 1 and seven additional patients with in-
fluenza A (H5N1) infection from whom at least 
one pharyngeal swab obtained before treatment 
and during treatment with oseltamivir was avail-
able. The swabs were collected in viral-transport 
medium and stored at −80°C.
virologic investigations
Virus isolation was performed in Madin–Darby 
canine-kidney cells in biosafety level III culture 
facilities, and influenza viruses were identified 
Table 1. Patients’ Characteristics and Clinical and Virologic Outcome.
Patient
Age (yr)/
Sex Admission*
Virus Detectable 
at End of 
Treatment†
H274Y in N1
 at End of 
Treatment† Clinical Outcome
Date
Day of 
Illness 
 1 13/F January 2005 2 Yes Yes Died on 8th day of illness
 2‡ 35/F January 2005 6 NA NA Died on 7th day of illness
 3 16/F December 2004 7 Yes NA Died on 20th day of illness
 4 18/F January 2005 6 Yes Yes Died on 20th day of illness
 5 26/F January 2005 4 NA NA Survived
 6§ 8/F January 2004 8 No — Survived
 7§ 23/M February 2004 7 No — Survived
 8 22/M February 2004 6 No — Survived
* All patients started oseltamivir treatment on the day of admission. 
† NA denotes not applicable owing to insufficient follow-up.
‡ Patient 2 was the mother of Patient 1.
§ This patient has been described previously.2
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by serotype-specific reverse-transcriptase–poly-
merase-chain-reaction (RT-PCR) assays and hem-
agglutination-inhibition assays, as described pre-
viously.2,5,6 For the diagnosis of influenza A (H5N1) 
infection, nucleic acids were purified from 100 μl 
of pharyngeal specimens and subtype-specific 
RT-PCR assays were performed as described pre-
viously.2,7,8 Quantitation of influenza A RNA was 
performed with the use of a real-time RT-PCR as-
say as described previously.6 The limit of detec-
tion of this assay is 1000 copies of RNA per mil-
liliter. Quantitative analyses of serial pharyngeal 
specimens were performed in a batch-wise fash-
ion. Positive and negative controls were included 
in all tests.
sequence analysis of neuraminidase genes
The sequence of the neuraminidase gene of ini-
tial viral isolates was analyzed as described pre-
viously,9 with the use of a BigDye Terminator 
A
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Figure 1. Serial Chest Radiographs Obtained from Patient 1.
A chest radiograph obtained at admission revealed a small focal pulmonary infiltrate in the right middle zone (Panel A). A chest radio-
graph obtained two days later showed minimal progression of the infiltrate (Panel B). On day 3, the pneumonia had progressed to 
involve most of the right middle zone (Panel C), and further progression was noted on day 4 (Panel D) and day 6 (Panel E), the day the 
patient died.
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Cycle Sequencing Kit (version 3.1, Applied Bio-
systems) on an ABI PRISM 3700 DNA Analyzer 
(Applied Biosystems). Sequence fragments were 
assembled and edited with the use of Lasergene 
software (version 6.0, DNASTAR). For direct se-
quencing of viral RNA from clinical specimens 
and follow-up isolates, a 200-bp fragment of N1 
encompassing amino acid position 274 was am-
plified (primers available on request) and sequenced 
with the use of a CEQ Dye Terminator Cycle Se-
quencing Kit on a CEQ8000 system (Beckman 
Coulter). Alignment and residue analyses were 
performed with the use of BioEdit software (ver-
sion 7). GenBank accession numbers of N1 se-
quences are shown in the Supplementary Appen-
dix (available with the full text of this article at 
www.nejm.org).
results
isolation of oseltamivir-resistant 
influenza a (h5n1) variants from patient 1
Influenza A (H5N1) virus infection was diagnosed 
in another local laboratory by RT-PCR assay of a 
pharyngeal swab obtained at admission. This spec-
imen was not available for further analysis. In our 
laboratory, influenza A (H5N1) virus was isolated 
from a throat swab obtained from Patient 1 on 
the fourth day of oseltamivir treatment (January 
25, 2005). Sequence analysis of the neuraminidase 
gene revealed the substitution of tyrosine for his-
tidine at amino acid position 274 (H274Y), asso-
ciated with high-level resistance to oseltamivir in 
influenza (N1) viruses.10 Analysis of the raw se-
quencing traces revealed the presence of a minor 
subpopulation of wild-type 274H variants among 
predominating 274Y mutants (Fig. 2). Virus was 
also isolated from a throat specimen obtained on 
January 28, 2005, two days after the completion 
of treatment. Sequence analyses of this strain as 
well as of viral RNA extracted directly from the 
swab also revealed the H274Y change in N1. Al-
though sequencing traces also revealed the pres-
ence of a minor wild-type 274H population in 
viral RNA from the swab, only 274Y variants were 
observed in the isolate, possibly reflecting over-
growth of the predominant mutant population dur-
ing culture. Determination of influenza A (H5N1) 
RNA levels showed that the viral load had in-
creased in the second specimen (Fig. 3).
virologic responses and isolation 
of a second oseltamivir-resistant strain 
Of 13 patients with RT-PCR–confirmed influenza 
A (H5N1) infection who were admitted to the Hos-
pital for Tropical Diseases in Ho Chi Minh City, 
Vietnam, between January 2004 and February 2005, 
at least one throat swab obtained before treatment 
and during treatment was available from 7 patients 
(Patients 2 through 8 in Table 1; additional infor-
mation on clinical features at admission, treatment, 
and outcomes is available in the Supplementary 
Appendix). Treatment with oseltamivir at the rec-
ommended dose and duration (75 mg twice daily 
for five days, with a weight-based reduction in the 
dose in children less than 13 years old) was begun 
on the day of admission in all patients. The remain-
ing six patients, for whom only specimens obtained 
at admission and not during treatment were avail-
able, presented at similar days of illness (median, 
six days; range, four to seven) and also began to 
receive oseltamivir therapy on the day of admis-
sion. Five of these patients died within one to eight 
days after admission (median, three).
Influenza A (H5N1) virus was isolated from 
throat swabs obtained at admission from six of the 
seven patients (Patients 2, 3, 5, 6, 7, and 8). Se-
quence analysis of the neuraminidase genes of 
these viruses revealed the wild-type 274H residue 
alone. Measurements of the viral RNA load in se-
quential throat specimens showed rapid declines 
to undetectable levels in four patients who sur-
vived, whereas viral RNA was still detectable at 
the completion of oseltamivir treatment in two 
patients who died (Patients 3 and 4 in Fig. 3). The 
remaining patient died during the second day af-
ter admission, at which time an increase in the 
viral RNA load was observed (Patient 2 in Fig. 3). 
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Figure 2. Sequencing Trace of the Neuraminidase Gene 
of Influenza A (H5N1) Virus Isolated from Patient 1 
on the Fourth Day of Oseltamivir Treatment. 
The arrow indicates the dominant T peak, with a small-
er C peak at nucleotide position 763. A C→T mutation 
at this position results in the substitution of tyrosine 
(encoded by TAC) for histidine (encoded by CAC) at 
amino acid position 274, which confers resistance to 
oseltamivir in N1-subtype influenza viruses.
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Direct sequencing revealed only wild-type 274H 
virus in the second specimen from this patient.
All subsequent throat specimens from Patients 
3 through 8 were cultured. Of these specimens, 
influenza A (H5N1) virus was isolated only from 
the last specimen from Patient 4, obtained three 
days after the completion of treatment (Fig. 3). 
Sequence analysis of this isolate revealed the 
H274Y substitution in N1. Although sequencing 
traces of the isolate revealed only mutant 274Y 
variants, direct sequencing of viral RNA from the 
same swab revealed evidence of a minor subpopu-
lation of wild-type 274H viruses similar to that in 
specimens from Patient 1. Patient 4 died of respi-
ratory failure six days after the isolation of resis-
tant virus. Direct sequences of viral RNA from 
swabs obtained at admission and after two days 
of treatment showed wild-type 274H virus alone. 
The limited sensitivity of the method precluded 
direct sequencing of further samples from this 
patient. Likewise, no direct sequences could be 
obtained from the last specimen obtained from 
Patient 3.
discussion
We report the isolation from two Vietnamese pa-
tients of influenza A (H5N1) viruses with a H274Y 
substitution in the neuraminidase gene, which 
confers high-level resistance to oseltamivir.10,11 
In contrast to the recent report of a partially re-
sistant influenza A (H5N1) virus isolated during 
once-daily prophylactic treatment with oseltami-
vir,11 the viruses in our patients were isolated 
during or shortly after a course of oseltamivir at 
therapeutic twice-daily doses, and mutant 274Y 
variants predominated. Furthermore, although the 
patient with partially resistant virus ultimately 
received oseltamivir at therapeutic doses and sur-
vived,11 both of our patients died.
Patient 1 was treated with doses of oseltami-
vir that were relatively high for her weight, espe-
cially during the first day of treatment. Moreover, 
in this patient, unlike most patients with influ-
enza A (H5N1) virus infection, treatment was 
started when the greatest clinical benefit could 
be expected: within 48 hours after the onset of 
symptoms. Indeed, her clinical condition remained 
stable during the first three days of treatment 
without the need for supplemental oxygen. How-
ever, on the fourth day of treatment she became 
progressively dependent on oxygen, her white-cell 
and platelet counts fell, and there was laboratory 
evidence of hepatitis. At the time of her death, 
the viral load in her throat had increased. These 
observations suggest that the development of drug 
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Figure 3. Influenza A (H5N1) Viral RNA Load in Throat Swabs from Eight Patients. 
Blue lines represent patients who survived influenza A (H5N1) virus infection, and red lines represent patients who 
died. The dashed horizontal line denotes the limit of detection of the RT-PCR assay. The arrows indicate the speci-
mens from which oseltamivir-resistant influenza A (H5N1) variants were isolated. No virus was isolated from any 
other specimen besides samples obtained at admission.
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resistance contributed to the failure of therapy 
and, ultimately, the death of this patient. In the 
second patient, the viral RNA load declined dur-
ing treatment, but not to undetectable levels. 
Whereas only wild-type 274H virus was detectable 
after two days of treatment, 274Y mutant virus 
was isolated shortly after treatment. Although a 
direct relationship between the emergence of re-
sistance and this patient’s death was less clear, the 
presence of replicating virus after 14 days of ill-
ness suggests an effect on the outcome.
The emergence of resistant influenza A (H5N1) 
variants during oseltamivir treatment should not 
be surprising. In adults with influenza A (H1N1) 
or (H3N2) virus infection, the development of re-
sistance to oseltamivir is rare, but resistant viral 
variants have been detected in up to 18 percent 
of children who receive oseltamivir.12-14 The dif-
ference in resistance rates between adults and 
children may be explained by the occurrence of 
a primary infection in children associated with 
higher rates of viral replication owing to a lack of 
previous immunity. Since humans have no previ-
ous immunity to influenza A (H5N1) virus, all 
human infections with this virus are primary 
infections. In addition, studies in animals indi-
cate particularly high levels of replication of cur-
rent influenza A (H5N1) strains.15,16
The efficacy of oseltamivir is unlikely to be 
optimal when treatment is instituted late in the 
course of illness, as has been the case in most 
patients with influenza A (H5N1) virus infection 
reported to date.1,2 However, antiviral treatment 
could still be expected to be beneficial when there 
is evidence of ongoing viral replication. Such ben-
efit is suggested by the rapid decline in the viral 
load to undetectable levels in all four survivors 
in the current series. In contrast, virus was still 
detectable at the end of treatment in three pa-
tients who died of the infection after receiving 
the full course of treatment, two of whom had 
oseltamivir-resistant virus isolated from throat 
specimens. Our observations suggest that at least 
in some patients with influenza A (H5N1) virus 
infection, treatment with the recommended dose 
of oseltamivir incompletely suppresses viral rep-
lication. Besides allowing the infection to proceed, 
such incomplete suppression provides opportuni-
ties for drug resistance to develop. Multiple mech-
anisms may account for inadequate viral suppres-
sion by oseltamivir, including overwhelming viral 
replication, as suggested by the results of studies 
in mice15 and altered pharmacokinetics in se-
verely ill patients, who are apt to have diarrhea.1-3 
Strategies aimed at improving antiviral efficacy 
(e.g., the use of higher doses, longer durations 
of therapy, or combination therapy) may deserve 
further evaluation. In addition, antiviral agents to 
which oseltamivir-resistant influenza viruses re-
main susceptible should be included in treatment 
arsenals for influenza A (H5N1) virus infections.
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